Navigation Links
Breakthrough in Migraine Treatment
Date:11/8/2011

LIEGE, Belgium, November 8, 2011 /PRNewswire/ --

PREMICE clinical trial proves Cefaly® medical device efficacy in migraine prevention and points out that Cefaly® has the best safety-efficacy ratio compared to other treatments.

On Monday 7th of November a press conference took place in Liege Science Park. Professor Jean Schoenen, principal investigator, neurologist and professor at Liege University (Belgium) presented the results of PREMICE (Prevention Migraine Cefaly) a multicenter randomized double-blind placebo controlled clinical trial for migraine prevention with the Cefaly® neurostimulator.

The clinical trial was conducted in 5 Belgian university hospitals on 67 patients. The results prove the efficacy of the Cefaly® compared to placebo for migraine prevention. At 3 months of treatment the 50% responder rate was significantly greater in the Cefaly® group (38,1%) than in the placebo group (12,1%). Seventy percents of patients declared they were satisfied or very satisfied with the Cefaly® treatment. The drug consumption reduction is very impressive in the Cefaly® group (-37%) compared to the placebo group (+0.5%). Cefaly® responder group drug consumption reduction was -75%!

Without noticeable side effects or contraindications, Cefaly® is very safe. Cefaly® has a similar efficacy than preventative drugs, but without side effects. Consequently, Cefaly® has the best safety-efficacy ratio of all migraine treatments.

Prof. Schoenen: "This clinical trial has been implemented according to the highest quality standard and it proves that Cefaly® is efficient for migraine prophylaxis. Efficacy is similar with the most efficient preventative drugs but with the great advantage of having no side effects."

Cefaly® is an innovative medical device protected by a series of patents. This is the first cranial external neurostimulation device on the market. Cefaly® neurostimulation is applied to the upper branch of the trigeminal nerve. A self-adhesive electrode is applied on the forehead and the device is placed on this electrode in the position of a pair of glasses. Very accurate pulses are transmitted through the electrode to the nerve endings of the trigeminal nerve.

STX-Med Company is a startup based in Liege (Belgium), which launched the Cefaly® technology project in 2005. The company STX-Med is ISO Medical. Cefaly® device has the medical CE-marked. It is available on the European market for 295 € and in Canada as well.

http://www.cefaly.com/


'/>"/>
SOURCE STX-Med
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetic Profile Identified for Alzheimers Patients Showing Heightened Response to Acceras Breakthrough Product Axona®
2. Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
3. SensoScientific Awarded Contract by Premier Health Care Alliance for its Breakthrough WI-FI Temperature Monitoring System
4. Major Diagnostic Breakthrough in Multiple Sclerosis Achieved with Advanced FONAR UPRIGHT® MRI
5. Antibody-Drug Conjugates 2011 - real breakthrough still to come. A Technology, Stakeholder and R&D Pipeline Analysis
6. Aging-in-Place Research Breakthroughs To Be Presented At Wireless Health 2011 Conference
7. Molecular Devices Releases Breakthrough TUNE Technology, Now Part of the SpectraMax® Paradigm® Multi-Mode Microplate Detection Platform
8. aTyr Pharma Expands Leadership Team to Advance New Breakthrough Medicines Based on Physiocrine Biology
9. Report on HIV Prevention Research Funding Says New Investment Critical to Capitalize on HIV Prevention Research Breakthroughs
10. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
11. CT Scans Unleash a Breakthrough in Catching Early Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 /PRNewswire/ ... ratings for global supply chains, has published the first annual edition of ... performance of more than 20,400 companies evaluated by EcoVadis, based on Scorecard ... and 2016. ... Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... WAUSAU, Wis. (PRWEB) , ... October 12, 2017 ... ... formulated standard products to meet the demand of today’s consumer and regulatory authorities ... team of probiotic experts and tested to meet the highest standard. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
Breaking Medicine News(10 mins):